Diabetes Obesity & Metabolism

Papers
(The H4-Index of Diabetes Obesity & Metabolism is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Diabetes, Obesity and Metabolism835
325
Issue Information272
Front Cover211
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic203
SemaGBA : A System Dynamics Model of the Semaglutide‐Responsive Gut‐Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight158
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study139
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy129
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”115
Involvement of the FTO A > T polymorphism in body composition and lipid profile changes after aerobic training in adults with overweight and obesity112
Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’102
Spillover effects of a nudge‐based dietary intervention on physical activity and sleep among adults with type 2 diabetes: Evidence from a randomised controlled trial99
Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials96
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover96
Pathway‐Specific Polygenic Risk Scores and Cardiorenal Complications in Asians With Type 2 Diabetes92
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic90
Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis89
Long‐term effects of metformin on offspring health: A review of current evidence and future directions88
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study83
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes83
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors80
Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based 72
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy71
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis71
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial68
Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study67
Effects of CB1R inverse agonist, INV ‐202, in patients with features of metabolic syndrome. A rand66
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?65
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial65
Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide64
Maternal Pregestational and Gestational Diabetes and Neuropsychiatric Risk in Offspring: A Binational Cohort Study63
The effects of antihypertensive drugs on glucose metabolism60
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry59
Disparities in heart failure deaths among people with diabetes in the United States: 1999–202059
Development of the health economic model for type 2 diabetes considering glycaemic variability56
Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized56
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease53
Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in typ53
Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabet53
Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–201952
Glycaemic Outcomes of a Novel Model‐Predictive‐Control‐Based Hybrid Closed‐Loop System in Chinese Adolescents and Adults With Type 1 Diabetes: A Multicentre Pivotal Trial52
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study50
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia50
CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination48
Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice47
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada47
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’47
0.079921960830688